Inside Molecular: Conversations Across BD Molecular Diagnostics

Learn how a large, multi-site study supports laboratory adoption of extragenital CT/NG testing on an automated, high throughput platform. This episode reviews importance of extragenital sample collection for STI testing, performance of extragenital STI testing on the BD COR™ System, and operational benefits of high-throughput automation.Disclaimer: Waters Corporation has acquired BD [Biosciences/Diagnostic Solutions]. BD remains the legal manufacturer until all required regulatory transfers are complete. Learn more: www.waters.com/bdtransaction 

This episode explores the latest in HPV screening guidelines, how extended genotyping can give you more clinical insights and how to easily interpret extended genotyping results using the ASCCP App.1 The program will also highlight the option of guidelines‑supported self‑collection* in a healthcare setting, including its potential to expand access to HPV screening, along with practical considerations for clinical workflow.2-51. ASCCP Guidelines: Journal of Lower Genital Tract Disease ():10.1097, January 10, 2025.2. Wentzensen N, et al. J Low Genit Tract Dis. 2025;29(2):109‑126.3. ACS: Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.700414. HRSA: Women’s Preventive Services Guidelines | HRSA accessed February 2026.5. ACOG: ACOG Statement issued January 5th, 2026.  *Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.Disclaimer: The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation (“Waters”). Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD’s regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: www.waters.com/bdtransaction

Welcome to Inside Molecular, a new podcast series exploring the BD Molecular Diagnostics portfolio—and the purpose and progress behind each solution.